Ardelyx/$ARDX
1D1W1MYTD1Y5YMAX
Capital at risk
About Ardelyx
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
- Ticker
- $ARDX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 489
- Headquarters
- Waltham, United States
- Website
- www.ardelyx.com
Ardelyx Metrics
BasicAdvanced
$877M
-
-$0.23
0.73
-
Price and volume
Market cap
$877M
Beta
0.73
52-week high
$8.40
52-week low
$3.51
Average daily volume
4.8M
Financial strength
Current ratio
3.342
Quick ratio
2.891
Long term debt to equity
1.885
Total debt to equity
1.896
Interest coverage (TTM)
-1.24%
Profitability
EBITDA (TTM)
-32.106
Gross margin (TTM)
75.02%
Net profit margin (TTM)
-12.35%
Operating margin (TTM)
-7.86%
Effective tax rate (TTM)
-0.41%
Revenue per employee (TTM)
$920,000
Management effectiveness
Return on assets (TTM)
-4.25%
Return on equity (TTM)
-38.61%
Valuation
Price to revenue (TTM)
1.912
Price to book
5.89
Price to tangible book (TTM)
5.89
Price to free cash flow (TTM)
-48.104
Free cash flow yield (TTM)
-2.08%
Free cash flow per share (TTM)
-0.073
Growth
Revenue change (TTM)
16.77%
Earnings per share change (TTM)
-4.00%
3-year revenue growth (CAGR)
75.89%
3-year earnings per share growth (CAGR)
-7.52%
10-year earnings per share growth (CAGR)
-22.48%
What the Analysts think about Ardelyx
Analyst ratings (Buy, Hold, Sell) for Ardelyx stock.
Analyst projections of the future price of Ardelyx stock.
Bulls say / Bears say
Ardelyx delivered record Q2 2026 product revenue of $118.1 million, up 31% year-over-year, marking its highest quarterly sales in company history. (GlobeNewswire) (Investing.com)
Core product performance remained strong, with IBSRELA revenue up 33% to $86.2 million and XPHOZAH revenue up 27% to $31.9 million, driven by increases in prescriptions and new prescribers. (GlobeNewswire) (Investing.com)
Ardelyx ended Q2 2026 with $281.8 million in cash, cash equivalents and short-term investments, underpinning its financial runway and supporting management’s expectation of achieving profitability in 2027. (GlobeNewswire) (Investing.com)
Ardelyx cut full-year 2026 IBSRELA guidance to $350 – $370 million and withdrew its $750 million XPHOZAH revenue target due to evolving reimbursement and market dynamics, signaling increased commercial uncertainty. (Investing.com) (GlobeNewswire)
Heightened utilization management processes and tighter prior authorization rules by payors slowed new IBSRELA patient starts, causing Q2 revenues to fall below internal expectations. (GlobeNewswire) (Investing.com)
Despite top-line growth, Ardelyx reported a net loss of $16.7 million in Q2, as R&D expenses jumped 66% and SG&A rose 20.7% year-over-year, extending its path to profitability. (GlobeNewswire) (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2026.
Ardelyx Financial Performance
Revenues and expenses
Ardelyx Earnings Performance
Company profitability
Upcoming events
No upcoming events
Ardelyx News
AllArticlesVideos
Funds containing Ardelyx
AllUSDGBPEUR
Fund name | Fund size | $ARDX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.09% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.09% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.